Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 5/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765511 | 0.86 | ALOX5AP (0.40) | PTPN1NOS1ALOX5APFEN1 | |
| SCHEMBL3752631 | 0.85 | NOS1 (0.43) | NOS1ATRTLR8ALOX5APFEN1 | |
| SCHEMBL3755480 | 0.84 | NOS1 (0.40) | PTPN1TRPA1NOS1ALOX5APFEN1 | |
| SCHEMBL3762339 | 0.83 | NOS1 (0.44) | NOS1 | |
| SCHEMBL3769692 | 0.83 | NOS1 (0.44) | PTPN1NOS1ATR | |
| SCHEMBL4524229 | 0.83 | PTPN1 (0.48) | PTPN1TRPA1TLR8CTSK | |
| SCHEMBL3760449 | 0.82 | NOS1 (0.44) | NOS1ATRTLR8 | |
| SCHEMBL3760969 | 0.82 | L3MBTL1 (0.47) | PTPN1NOS1ATR | |
| SCHEMBL4452427 | 0.81 | HSP90AA1 (0.46) | PTPN1NOS1ATR | |
| SCHEMBL3765833 | 0.81 | NOS1 (0.53) | NOS1ATRTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | claimed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885TRPA1 4636/4885NOS1 2154/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885TRPA1 4636/4885NOS1 2154/4885 |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | PTPN1 2905/4885TRPA1 4636/4885NOS1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.